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Abstract
Background: Fibroblasts are implicated in sub-epithelial fibrosis in remodeled asthmatic airways
and contribute to airway inflammation by releasing cytokines and other mediators. Fibroblast
activity is influenced by members of the leukotriene family of bronchoconstrictor and inflammatory
mediators, but it is not known whether human bronchial fibroblasts can synthesize leukotrienes.
Methods: The expression of leukotriene biosynthetic enzymes and receptors was investigated in
primary fibroblasts from the bronchi of normal and asthmatic adult subjects using RT-PCR,
Western blotting, immunocytochemistry and flow cytometry.
Results: These techniques revealed that human bronchial fibroblasts from both subject groups
constitutively express 5-lipoxygenase, its activating protein FLAP, the terminal enzymes leukotriene
A4 hydrolase and leukotriene C4 synthase, and receptors for leukotriene B4 (BLT1) and cysteinyl-
leukotrienes (CysLT1). Human bronchial fibroblasts generated immunoreactive leukotriene B4 and
cysteinyl-leukotrienes spontaneously and in increased amounts after calcium-dependent activation.
Flow cytometry showed that human bronchial fibroblasts transformed to a myofibroblast-like
phenotype by culture with transforming growth factor-β1  expressed 320–400% more
immunofluorescence for leukotriene C4 synthase and CysLT1 receptors, with 60–80% reductions
in leukotriene A4 hydrolase and BLT1 receptors.
Conclusion: These results indicate that human bronchial fibroblasts may not only respond to
exogenous leukotrienes but also generate leukotrienes implicated in narrowing, inflammation and
remodeling of the asthmatic airway.
Background
Airway inflammation and remodeling are prominent fea-
tures of the asthmatic lung, characterized by leukocyte
infiltration, oedema and mucus hypersecretion, com-
bined with sub-epithelial fibrosis and smooth muscle
hypertrophy. Fibroblasts are the most abundant cell type
of the lung interstitium and play a significant role in air-
way inflammation by expressing an array of cytokines and
adhesion molecules which play key roles in infiltration
and activation of eosinophils and other leukocytes [1].
Fibroblasts can be transformed into the myofibroblast
phenotype, which express contractile proteins and have
an increased capacity for collagen deposition, in a process
regulated by cytokines, growth factors and matrix compo-
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nents [2]. Myofibroblasts are also critical to the develop-
ment of sub-epithelial fibrosis, which is due to enhanced
accumulation of the repair-like proteins fibronectin,
tenascin, and collagens (types I, III and V) [3]. Increased
numbers of myofibroblasts are found beneath the bron-
chial epithelium of asthmatic patients compared to nor-
mal subjects, and their numbers correlate with the degree
of collagen deposition [4].
Leukotrienes are a family of lipid inflammatory mediators
of central importance to the pathogenesis of asthma. As
well as inducing bronchoconstriction, airway oedema,
mucus secretion and eosinophil infiltration [5], they may
also play a role in remodeling. Members of the cysteinyl-
leukotriene sub-family increase the proliferation of bron-
chial epithelial cells and airway smooth muscle cells [6,7].
Leukotrienes also increase the proliferation of fibroblasts
and enhance their release of collagens and collagenase
[8,9]. In a murine model of chronic allergic asthma with
fibrosis, blockade of cysteinyl-leukotriene activity by
montelukast significantly reduced eosinophil infiltration,
mucus plugging, and smooth muscle hyperplasia, and
completely prevented the development of sub-epithelial
fibrosis [10]. Mice depleted of leukotrienes by deletion of
the 5-lipoxygenase (5-LO) gene are protected against lung
fibrosis induced by bleomycin [11]. In asthmatic patients,
bronchoconstrictor responses to allergen and other
asthma triggers are associated with rapid de novo synthesis
of leukotrienes by airway mast cells, eosinophils and
other leukocytes, but the cellular sources of leukotrienes
involved in airway remodeling are not clear. We postulate
that human bronchial fibroblasts (HBFs) themselves are
capable of generating leukotrienes that may influence
fibrosis and other remodeling processes by autocrine or
paracrine mechanisms.
Leukotriene synthesis is most apparent in cells of myeloid
origin, in which activation and calcium influx leads to the
liberation of arachidonic acid from cell membranes by
phospholipase A2. Arachidonate is donated to 5-LO by
the 5-LO activating protein (FLAP) and oxidized to the
unstable epoxide, leukotriene (LT)A4. In some cell types,
the predominant activity of LTA4  hydrolase generates
LTB4, while in other cell-types the integral membrane pro-
tein LTC4 synthase conjugates LTA4 with glutathione to
provide the first of the cysteinyl-leukotrienes, LTC4. After
carrier-mediated export, LTC4 with its extracellular metab-
olites LTD4 and LTE4 exert bronchoconstrictor and pro-
inflammatory activity at specific G-protein coupled recep-
tors termed cysteinyl-leukotriene receptor type 1 (CysLT1)
[12]. LTB4 acts chemotactically at high-affinity BLT1 recep-
tors [13].
We therefore investigated whether HBFs from normal and
asthmatic subjects can express mRNA and protein for the
5-LO pathway enzymes and generate biologically-active
leukotrienes, either constitutively or after treatment with
autacoids, cytokines and growth factors.
Methods
Reagents
Materials were purchased as follows: Biotinylated swine
anti-rabbit antibody, biotinylated rabbit anti-mouse anti-
body, streptavidin-biotin-horseradish-peroxidase conju-
gate, rabbit and goat sera, rabbit immunoglobulins and
mouse IgG1 were from DAKO Ltd (High Wycombe, Bucks,
UK). Omniscript RT-PCR kits were purchased from Qia-
gen (Crawley, UK), goat anti-rabbit/PE, rabbit anti-goat/
FITC and rabbit anti-mouse/FITC antibodies from South-
ern Biotechnologies Ltd (Birmingham, Alabama, USA),
and Biotrak EIA kits for LTC4/D4/E4 and for LTB4 from
Amersham Pharmacia Biotech (Little Chalfont, Bucks,
UK). DMEM, penicillin/streptomycin, Trizol, FCS, EGF,
human serum, and trypsin/EDTA were from Gibco Life
Technologies Ltd (Paisley, UK). TGF-β1, protease inhibitor
cocktail, calcium ionophore A23187, saponin, dexameth-
asone, histamine, bradykinin and antibodies against
actin, myosin and vimentin were from Sigma Chemical
Co. (Poole, Dorset, UK). Interleukin (IL)-1β, tumor
necrosis factor-α (TNF-α) and IFN-γ were from R&D Sys-
tems (Abingdon, UK). Bis-acrylamide solution, sodium
dodecyl sulphate and molecular weight markers were
from Bio-Rad (Hemel Hempstead, UK). Polyclonal anti-
bodies recognizing the C-terminal amino acids 331–352
of the BLT1 receptor and the C-terminal amino acids 318–
337 of the CysLT1 receptor were purchased from Cayman
Chemical (Ann Arbor, MI, USA), as were the CysLT1
receptor blocking peptide, LTB4, LTD4 and MK-571. Rab-
bit antisera directed against 5-LO, FLAP, LTA4 hydrolase
[14], goat antibody to the whole human CysLT1R protein
[15] and human 5-LO and FLAP protein standards were
kind gifts from Dr JF Evans (Merck & Co., West Point, Pa,
USA). LTC4 synthase antibody does not cross-react with
FLAP or with microsomal glutathione-S-transferase type II
(MGST-II) [16].
Culture of primary human lung fibroblasts
Fibroblasts were grown as described [17] from explants of
bronchial biopsy tissue from normal, non-atopic, non-
smoking adult volunteers (4 males, 1 female) with a mean
forced expiratory volume in one second (FEV1) of 95.8 ±
2.1% of predicted and a provocation concentration of
inhaled histamine to reduce FEV1 by 20% (histamine
PC20) >32 mg/ml, and from mild-moderate adult asth-
matic donors (3 male, 2 female) with mean FEV1 of 76.4
± 2.7% of predicted and geometric mean histamine PC20
of 2.24 mg/ml (95% confidence interval 0.71 – 7.94).
Subjects had been free of respiratory tract infections for at
least 4 weeks before the study. All subjects gave written
informed consent to the study, which was in complianceRespiratory Research 2006, 7:102 http://respiratory-research.com/content/7/1/102
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with the Helsinki Declaration and approved by the South-
ampton & Southwest Hampshire Local Research Ethics
Committee (130/98). Six submucosal biopsies from each
subject were obtained as described [17]; biopsies were cut
into pieces with sterile scalpel blades in a Petri dish con-
taining DMEM (containing 10% FCS, 50 U/ml penicillin,
50 μg/ml streptomycin and 2 mM L-glutamine). The tis-
sues were cultured in a humidified incubator (37°C, 5%
CO2) for approximately one week, during which fibrob-
lasts migrated from the tissue and proliferated on the base
of the culture dish. Separate cultures were maintained
from each donor; cultures were fed every 2–3 days and
passaged weekly. Cells for experiments were between pas-
sages five and seven for both normal and asthmatic
donors. Before experimentation, cells were incubated in
Ultraculture serum-free medium (BioWhittaker, Woking-
ham, UK) for 24 hours. The cells were characterized by
flow cytometry using antibodies against the mesenchymal
cell marker vimentin and the myofibroblast cell marker α-
smooth muscle actin. All cell lines were uniformly immu-
nopositive for vimentin (Figure 2) and had consistently
low levels of α-smooth muscle actin (Figure 4), indicating
that the cultures were uncontaminated fibroblasts.
Isolation of peripheral blood leukocytes
In some experiments, peripheral blood leukocytes (PBL),
obtained from normal venous blood by dextran sedimen-
tation, were used as positive controls. Blood (20 ml) anti-
coagulated with EDTA was mixed with 5% dextran (MW
70 kD) in PBS with 2% FCS. After sedimentation for 60
min, the leukocyte-rich upper layer underwent hypotonic
red cell lysis in distilled water for 45s. Following centrifu-
gation, PBL comprised 60–65% neutrophils, 30–40%
mononuclear cells, 1–3% eosinophils and <1%
basophils, as determined by Diff-Quik (Brownes Ltd, UK)
staining, with a viability of >95% by Trypan Blue exclu-
sion.
Reverse-transcription PCR
Total RNA in cells grown in 10 cm2 Petri dishes was iso-
lated using the Trizol method (Gibco). Cells were homog-
enized in Trizol with glycogen and extracted with
chloroform. After centrifugation, RNA in the upper aque-
ous phase was precipitated with isopropanol overnight at
-20°C, washed twice in 80% ethanol and resuspended in
DEPC-treated water. For first-strand cDNA synthesis, 2 μg
RNA was incubated for one hour at 37°C in a total vol-
ume of 20 μl of DEPC-treated water with 2 μl of 10 × RT
buffer, 2 μl of dNTP mix, 2 μl of oligo-dT primer (10 μM),
1 μl of RNase inhibitor (10 U/μl) and 1 μl of Omniscript
reverse transcriptase, according to the Qiagen kit protocol.
PCR primer sequences were designed with Oligo Primer
Analysis Software version 5 (National Biosciences, Inc)
and synthesized by MWG Biotech (Milton Keynes, UK)
(Table 1). PCR was performed with 2 μl of reverse tran-
scription products in a total volume of 25 μl of DEPC-
treated water, containing 10 × PCR buffer (2.5 μl), Mg2+
(minimum 25 mM), dNTP (10 mM), Jumpstart (2.5 U/
μl) and 1 μl of each upper and lower primer per tube (or
1.5 μl of GAPDH primers). Using a Peltier Thermal Cycler
(PTC-225, MJ Research), thirty PCR cycles were carried
out at 96°C for 5 min, 94°C for 30 s, 54°C (for CysLT1R),
58°C (for 5-LO, FLAP, and LTA4 hydrolase), 57°C (for
GAPDH) or 64°C (for LTC4synthase) for 30 s, followed by
72°C for 7 min. Reaction products were separated on a
2% agarose gel and bands were visualized using ethidium
bromide (0.1%). The gel was scanned using a Fluorimager
595 (Molecular Dynamics, Little Chalfont, UK) with
Phoretix advanced software (Nonlinear Dynamics Ltd,
Newcastle upon Tyne, UK). GAPDH was the positive con-
trol, and as a negative control, PCR was carried out in the
absence of cDNA for each set of primers. Control experi-
ments using genomic DNA instead of cDNA showed no
bands for either the 5-LO, FLAP, LTA4H or LTC4S primers.
Flow cytometry
For immunofluorescent staining of intracellular proteins
(5-LO, FLAP, LTA4  hydrolase, LTC4  synthase, actin,
myosin and vimentin) and the C-terminal intracellular
epitope of the BLT1 receptor and the CysLT1 receptor,
cells were detached from plastic ware with trypsin/EDTA
and fixed in 4% paraformaldehyde in PBS for 30 min on
ice. After washing in PBS, cells were treated with glycine
buffer (0.1 M in PBS) for 10 min to prevent antibody/
paraformaldehyde interactions. After two further washes
in PBS, cells were permeabilised in PBS containing
saponin (0.5%) and BSA (0.5%) for 30 min. Subsequent
steps were performed in saponin-PBS to prevent reversal
of permeabilisation. For CysLT1 (whole protein), immun-
ofluorescent staining was performed on unfixed cells
without permeabilisation. In this case cells were detached
with non-enzymatic cell dissociation medium to prevent
Table 1: Primer sequences for RT-PCR analysis of 5-LO pathway 
enzymes and receptors in human bronchial fibroblasts.
Enzyme/
Receptor
Primer Sequence
5-LO upper 5'-TAC ATC GAG TTC CCC TGC TAC-3'
lower 5'-GTT CTT TAC GTC GGT GTT GCT-3'
FLAP upper 5'-GAT GCG TAC CCC ACT TTC CTC-3'
lower 5'-GAA TAT GCC AGC AAC GGA CAT-3'
LTA4H upper 5'-GCC CGA GAT AGT GGA TAC CTG-3'
lower 5'-TTT TTG CTC AAA GCG ATA GGA-3'
LTC4S upper 5'-CTG TGC GGC CTG GTC TAC CGT 3'
lower 5'-GGG AGG AAG TGG GCG AGC AG-3'
CysLT1 upper 5'-CCG CTG CCT TTT TAG TCA GTT TC-3'
lower 5'-GGG TAC ATA AGT CAC GCT GGA CA-3'
GAPDH upper 5'-GCT TGT CAT CAA TGG AAA TCC-3'
lower 5'-AGG GGA TGC TGT TCT GGA GAG-3'Respiratory Research 2006, 7:102 http://respiratory-research.com/content/7/1/102
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proteolysis of extracellular receptor epitopes and washed
in FACS buffer (PBS containing 1% BSA and 0.1% sodium
azide). All subsequent steps were also performed using
FACS buffer.
Optimal dilutions of antibodies were prepared in the rel-
evant buffer (with or without saponin) containing 10%
human serum. Anti-human 5-LO, FLAP, LTA4 hydrolase,
LTC4 synthase, and BLT1 antibodies were raised in rabbits,
CysLT1 in goat, and actin, myosin and vimentin antibod-
ies in mice. Cells were washed three times and incubated
with optimal dilutions of the appropriate fluorescence-
labeled secondary antibody (goat anti-rabbit/PE, rabbit
anti-goat/FITC or rabbit anti-mouse/FITC) for 30 min.
After washing, cells were re-suspended in 250 μl buffer
and immunofluorescence was assessed by FACScan flow
cytometer; analysis was by Cellquest software (Becton
Dickinson).
Immunoblotting
Immunoblotting for leukotriene pathway enzymes was
performed essentially as described [18]. Cells were sus-
pended in 250 μl protease inhibitor cocktail and soni-
cated on ice for three 10 s pulses at 16 μm (Soniprep).
Total cellular protein concentrations were equalised to 1
mg/ml after analysis by DC protein assay (Bio-Rad, Hemel
Hempstead, UK). SDS reducing buffer (0.06 M Tris, 10%
SDS, 10% β-mercaptoethanol, 50% glycerol, 0.05%
bromophenol blue) was added to the cell lysate (1:3)
before heating at 80°C for 5 min. Electrophoresis of 5-LO
and LTA4 hydrolase required 10% polyacrylamide gels,
while FLAP and LTC4synthase were run on 12% gels. Each
lane was loaded with 25 μl of cell lysate (or 5 μl molecular
weight markers) and electrophoresed at 0.04 Amps for 45
min on Bio-Rad mini-Protean II equipment. Proteins were
semi-dry transferred to nitrocellulose membrane (20 V,
20 min) and treated with PBS containing 5% dry milk
powder overnight to reduce non-specific binding. For
Western blotting, antibodies were made up in PBS with
0.05% Tween non-ionic detergent and 1% BSA. Opti-
mally diluted primary antibodies were applied for 90 min
before the membrane was washed (3 × 5 min) in PBS with
0.05% Tween. The secondary antibody (biotinylated
swine-anti-rabbit IgG) was applied for 90 min. After
washing, SAB-HRP conjugate was applied for 1 hour. After
washing, protein bands were visualised using SuperPlus
chemiluminescent substrate (Amersham Pharmacia Bio-
tech, UK).
Immunocytochemistry
Fibroblasts were cultured on glass coverslips for immuno-
cytochemistry. When confluent, cells were washed in PBS,
fixed in cold methanol for 10 min then washed again. To
irreversibly block endogenous peroxidases, coverslips
were incubated with 0.3% hydrogen peroxide solution
with 0.1% sodium azide for 30 min at room temperature.
After washing three times in TBS for 5 min, non-specific
binding was reduced by incubation with DMEM contain-
ing 10% FCS and 1% BSA for 30 min. Rabbit or goat pol-
yclonal primary antibodies were applied for 1 hour at
titrated dilutions. After washing, biotinylated secondary
antibody was applied for 1 hour followed by streptavidin-
biotin-horseradish peroxidase conjugate for 1 hour.
Immunostaining was visualized using AEC chromagen
and the nuclei counterstained by Meyer's haematoxylin.
Enzyme immunoassays
Cell culture supernatants were stored at -20°C before
assay of LT concentrations using Biotrak LTC4/D4/E4 and
LTB4  EIA kits in accordance with the manufacturer's
instructions. The cysteinyl-LT EIA was calibrated with
standard LTC4 from 0.75–48 pg/well, and used a polyclo-
nal antiserum that cross-reacts with LTC4 (100%), LTD4
(100%), LTE4 (70%) and their 11-trans isomers, but neg-
ligibly with LTB4 (0.3%), various prostanoids or glutath-
ione (<0.006%). The LTB4  EIA was calibrated with
standard LTB4 from 0.30–40 pg/well and used a polyclo-
nal antiserum that cross-reacts with LTB4 (100%), 20-OH-
LTB4 (2%) and 6-trans-LTB4 (25.5%), but negligibly with
LTC4, LTD4, or products of 12-LO or 15-LO. Following
incubations, cells were detached and counted in order to
express EIA results as pg/106 cells.
Statistical analyses
Results are expressed as mean ± SEM, but Normality was
not assumed and statistical comparisons were performed
using non-parametric tests on SPSS version 12.0 for Win-
dows (Microsoft Systems Inc). Paired comparisons were
performed by Wilcoxon sign rank tests, and where the
number of possible comparisons was large, overall signif-
icance was first assessed by a Friedman test. The Mann-
Whitney  U  test was used to compare unpaired data
between the asthmatic and normal subject groups. p ≤
0.05 was accepted as significant.
Results
Basal expression of LT pathway enzymes in human 
bronchial fibroblasts
To examine whether HBFs constitutively express leukot-
riene pathway enzymes, baseline levels of 5-LO, FLAP,
LTA4 hydrolase and LTC4 synthase mRNA and protein
were assessed by RT-PCR, SDS-PAGE/Western immunob-
lotting, immunocytochemistry and flow cytometry. A
non-quantitative RT-PCR approach, using GAPDH as a
positive control, was sufficient to establish the presence of
mRNA transcripts for 5-LO, FLAP, LTA4 hydrolase and
LTC4 synthase, as well as for the BLT1 and CysLT1 recep-
tors in cultured fibroblasts (Figure 1A). The lengths of the
amplicons generated were consistent with the expected
values (124 bp, 210 bp, 291 bp, 155 bp and 248 bpRespiratory Research 2006, 7:102 http://respiratory-research.com/content/7/1/102
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respectively), and the LTC4S amplicons had the expected
sequence.
SDS-PAGE/Western immunoblotting (Figure 1B) revealed
that fibroblasts also constitutively expressed 5-LO, FLAP,
LTA4 hydrolase and LTC4 synthase proteins, with immu-
nopositive bands corresponding to the expected molecu-
lar weights of approximately 80 kDa, 18 kDa, 70 kDa and
18 kDa respectively. 5-LO and FLAP in fibroblasts co-
migrated with recombinant 5-LO and FLAP standards,
and the intensities of immunostaining for all four
enzymes were similar to those observed in equal amounts
of total cellular protein extracted from PBL (Figure 1B).
Fibroblasts from both subject groups expressed similar
levels of mRNA and protein for the 5-LO pathway
enzymes and leukotriene receptors (normal subjects, n =
5; mild-moderate asthmatic patients, n = 5).
Baseline expression of 5-LO pathway enzymes and recep-
tors in fibroblasts was also assessed by flow cytometry.
Flow cytometry plots for the biosynthetic proteins (5-LO,
FLAP, LTA4  hydrolase, LTC4  synthase) and receptors
(BLT1, CysLT1) are shown in Figure 2; these are represent-
ative plots of control data from the nine subjects shown in
Table 3. The presence of CysLT1 was further confirmed by
flow cytometry with a polyclonal antibody recognizing
the C-terminal amino acids 318–337 (Cayman Chemi-
cal), in the presence and absence of a CysLT1 receptor
blocking peptide (Cayman Chemical) corresponding to
the target sequence of this antibody. There were no inher-
ent differences in surface expression of 5-LO pathway
enzymes and leukotriene receptors in fibroblasts from
mild-moderate asthmatic patients (n = 5) compared with
normal subjects (n = 5)(Table 2).
Immunocytochemistry was used to visualize cellular
expression of the 5-LO pathway enzymes and LT recep-
tors; representative photomicrographs of normal fibrob-
lasts are shown in Figure 3. Positive AEC immunostaining
(red) was observed for 5-LO, FLAP, LTA4 hydrolase, LTC4
synthase, BLT1 receptors and CysLT1 receptors (Figure 3A–
F), while antibody-negative controls showed no immu-
nostaining (Figure 3G, H).
Effect of transforming growth factor-β on expression of 5-
LO pathway enzymes and LT receptors in human 
bronchial fibroblasts
Stimulation with transforming growth factor-β1(TGF-β1)
is known to transform fibroblasts into a more contractile,
myofibroblast-like phenotype [19], accompanied by
increased expression of the contractile proteins α-smooth
muscle actin and myosin. The effect of TGF-β1 (10 ng/ml,
72 hours) on the expression of 5-LO pathway enzymes
and LT receptors was therefore examined in fibroblasts by
flow cytometry. As expected, TGF-β1 stimulation increased
the median immunofluorescence intensity (MFI) for actin
nearly 10-fold from 14.6 ± 3.4 to 135.1 ± 41.8 units (p =
0.008) and doubled that for myosin from 2.0 ± 0.3 to 3.9
± 1.4 (p = 0.021)(n = 9). Treatment with TGF-β1 did not
Constitutive expression of LT pathway enzyme mRNA and  protein in human bronchial fibroblasts Figure 1
Constitutive expression of LT pathway enzyme 
mRNA and protein in human bronchial fibroblasts. 
(A) RT-PCR analyses of human bronchial fibroblasts (F) from 
a representative normal donor in duplicate to show equal 
loading. GAPDH was the internal positive control, and PCR 
was carried out in the absence of RT product as a negative 
control (-). The amplicons generated were consistent with 
the sizes expected for GAPDH (450 bp), 5-LO (124 bp), 
FLAP (210 bp), LTA4H (291 bp), LTC4S (155 bp) and CysLT1 
(248 bp). Panel (B) shows an immunoblot of lysates from 
fibroblasts from a representative asthmatic patient (F) com-
pared with peripheral blood leukocytes (PBL). Each lane rep-
resents the same amount of total cellular protein. 
Recombinant protein standards are shown for 5-LO and 
FLAP (+). n = 5 normals, n = 5 asthmatics.
B
80 kDa
18 kDa
70 kDa
18 kDa
F          PBL       (+)
5-LO
FLAP
LTA4H
LTC4S
124 bp
210 bp
291 bp
155 bp
5-LO
FLAP
LTA4H
LTC4S
GAPDH
A
FF (-)
450 bp
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alter the MFI for 5-LO (2.2 ± 0.6) or FLAP (2.8 ± 0.7), but
LTC4  synthase immunofluorescence increased five-fold
from 0.06 ± 0.02 to 0.3 ± 0.1 units (p = 0.044), while
CysLT1R increased four-fold from 7.3 ± 1.5 to 30.6 ± 9.0
(p = 0.011). Conversely, expression of LTA4 hydrolase and
BLT1 was significantly reduced by TGF-β1 (MFI from 2.8 ±
0.6 to 1.2 ± 0.3 units, p = 0.021, and from 5.1 ± 2.2 to 0.9
± 0.2, p = 0.012, respectively) (Figure 4). No significant
differences were found between the mild-moderate asth-
matic and normal subject groups in their responses to
TGF-β1 (Figure 4).
Effect of TGF-β1 on A23187-induced synthesis of cysteinyl-
leukotrienes and LTB4
To investigate the enzymatic activity of the 5-LO pathway
in human bronchial fibroblasts, production of LTB4 and
total cysteinyl-LTs was quantified by EIAs. Following 72
hours incubation with or without TGF-β1 (10 ng/ml),
fibroblasts were incubated for a further two hours in the
presence or absence of the divalent cation ionophore
Immunocytochemistry for 5-LO pathway enzymes and LT  receptors in human bronchial fibroblasts Figure 3
Immunocytochemistry for 5-LO pathway enzymes 
and LT receptors in human bronchial fibroblasts. Rep-
resentative photomicrographs of fibroblasts from one donor. 
Fibroblasts were grown to confluence on coverslips and 
immunostained using primary antibodies against (A) 5-LO, 
(B) FLAP, (C) LTA4 hydrolase, (D) LTC4 synthase, (E) BLT1 
receptors and (F) CysLT1 receptors. Staining with equivalent 
concentrations of (G) rabbit serum and (H) goat serum are 
shown as negative controls for A-E and F, respectively. Mag-
nification x400. Positive immunostaining appears red (AEC) 
against the blue nuclear counterstain (Meyer's haematoxylin).
AB
C D
EF
GH
Flow cytometry of baseline expression of 5-LO pathway  enzymes and LT receptors in human bronchial fibroblasts Figure 2
Flow cytometry of baseline expression of 5-LO path-
way enzymes and LT receptors in human bronchial 
fibroblasts. Flow cytometric histograms showing specific 
immunostaining for the cytoskeletal protein vimentin as a 
positive control, 5-LO, FLAP, LTA4H, LTC4S, BLT1 and 
CysLT1R (open curves) in fibroblasts from one representa-
tive normal donor compared to the relevant isotype controls 
(filled curves). n = 5 normals, n = 4 asthmatics.
Vimentin (+)
FLAP 5-LO
LTA4 H LTC4S
BLT1 CysLT1
Fluorescence intensity
E
v
e
n
t
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A23187 (1 μM). Immunoreactivity for cysteinyl-LTs and
LTB4  was readily detectable in fibroblast supernatants
from unstimulated cells (33.8 ± 8.3 and 182.1 ± 86.9 pg/
106 cells respectively). Stimulation with ionophore signif-
icantly increased the mean production of cysteinyl-LTs by
approximately 60% to 54.2 ± 9.4 pg/106 cells (p = 0.028),
and production of LTB4 increased by 80% to 327 ± 150
pg/106 cells (p = 0.015; n = 9) (Figure 5). Culture for 72
hours with TGF-β1 had no effect on the amounts of LTB4
and LTC4 released either in unstimulated cells or in those
stimulated with A23187 (Figure 5). Fibroblasts from both
subject groups produced similar amounts of cysteinyl-LTs
and of LTB4 and responded to stimulation to a similar
degree.
Effects of growth factors, inflammatory cytokines and 
autacoids on expression of 5-LO pathway enzymes and LT 
receptors
Fibroblasts were cultured for 24 hours with either epider-
mal growth factor (EGF) (10 ng/ml), a combination of IL-
1β, TNF-α and IFN-γ (each at 10 ng/ml), LTB4 (10 nM),
LTD4 (10 nM), bradykinin (10 μM) or histamine (10 μM)
and flow cytometry was used to quantify immunofluores-
cence for the leukotriene pathway enzymes and receptors.
Compared to control medium, none of these stimuli sig-
nificantly increased the expression of 5-LO, FLAP, LTA4
hydrolase, LTC4 synthase, BLT1 or CysLT1 (Table 3). Treat-
ment with histamine for 24 hours caused a small but sig-
nificant decrease in 5-LO (MFI from 9.1 ± 2.0 to 6.4 ± 1.9,
p = 0.036) and treatment with LTB4 caused a significant
decrease in LTC4S (MFI from 1.5 ± 0.7 to 0.8 ± 0.3, p =
0.047); these changes may have arisen from the large
number of statistical comparisons performed on Table 3
as Friedman's test for non-parametric multiple compari-
sons suggested no overall effect. No significant differences
were found between the subject groups in their responses
to treatment with ionophore, growth factors, inflamma-
tory cytokines or autacoids.
Effects of dexamethasone and MK-571 on expression of 5-
LO pathway enzymes and LT receptors
Flow cytometry was used to quantify the effects of cultur-
ing fibroblasts for 24 hours with the glucocorticoid dex-
amethasone (1 μM) or the CysLT1 receptor antagonist MK-
571 (10 nM). Friedman tests indicated no overall effects
of either drug on any 5-LO pathway protein or LT recep-
tor, although individual comparisons using Wilcoxon
sign rank tests suggested that MK-571 modestly reduced
the expression of FLAP (p < 0.05) and increased expres-
sion of LTC4 synthase (p < 0.043), while dexamethasone
produced non-significant reductions of 25–53% in
immunofluorescence for 5-LO (p < 0.07) and LTA4 hydro-
lase (p < 0.07) (n = 9)(Table 4). No significant differences
were found between the subject groups in their responses
to dexamethasone or MK-571.
Discussion
Cysteinyl-leukotrienes are key mediators of bronchocon-
striction and airway eosinophilia in the asthmatic lung.
Studies in animal models have also implicated these auta-
coids in airway fibrosis [10,11], and exogenous cysteinyl-
Effects of TGF-β on expression of contractile proteins, 5-LO  pathway enzymes and leukotriene receptors in fibroblasts  from normal and asthmatic subjects Figure 4
Effects of TGF-β on expression of contractile pro-
teins, 5-LO pathway enzymes and leukotriene recep-
tors in fibroblasts from normal and asthmatic 
subjects. Fibroblasts were cultured in the presence 
(+TGFβ) and absence (-TGFβ) of TGF-β1 (10 ng/ml) for 72 
hours before staining with specific antibodies for actin, 
myosin, 5-LO, FLAP, LTA4H, LTC4S, BLT1 and CysLT1R and 
analysis by flow cytometry. Horizontal bars represent median 
values of all experiments where data points from normal 
donors are presented as a hollow square (n = 5) and asth-
matic donors as a filled circle (n = 4).
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LTs can enhance proliferation and collagen release by
fibroblasts  in vitro [8,9]. Our study investigated the
hypothesis that human bronchial fibroblasts may express
the 5-LO pathway and directly generate cysteinyl-LTs and
the chemotactic agent LTB4.
Approaches at the levels of mRNA, protein and lipid prod-
uct demonstrated constitutive expression and activity of
the key LT biosynthetic enzymes 5-LO, FLAP, LTA4 hydro-
lase and LTC4 synthase in fibroblasts from normal and
asthmatic bronchi. The data thus confirm that primary
HBF express the distal enzyme (LTA4 hydrolase) required
to complete LTB4 synthesis [20], but also show for the first
time that HBF also express the proximal enzymes 5-LO
and FLAP required to initiate synthesis of the unstable
intermediate LTA4, as well as the terminal LTC4 synthase
required to generate the first of the cysteinyl-LTs. Consti-
tutive expression of each enzyme was revealed at the
mRNA level by RT-PCR (Figure 1A), and also at the level
of immunoreactive protein by Western blotting (Figure
1B), flow cytometry (Figure 2), and immunocytochemis-
try (Figure 3). The primary antibodies used in these latter
experiments are highly selective; the rabbit antibody to 5-
LO does not cross-react with other human lipoxygenases,
such as 12-LO or 15-LO [14]. The rabbit antiserum to
FLAP does not cross-react with LTC4 synthase, despite the
strong sequence homology of the two enzymes [21], and
conversely, the LTC4 synthase antiserum does not cross-
react with FLAP nor with microsomal glutathione-S-trans-
ferase type II [16].
The enzymatic activity of the 5-LO pathway was con-
firmed using highly-specific enzyme immunoassays for
released cysteinyl-LTs and LTB4. Each sub-family of LT was
readily detected in fibroblast-con ditioned media from
normal and asthmatic donors, both spontaneously and in
increased amounts after stimulation with the calcium
ionophore A23187 (Figure 5), which activates phosphol-
ipase A2  and 5-LO by increasing intracellular Ca2+.
Although the levels of expression of 5-LO, FLAP, LTA4
hydrolase and LTC4 synthase proteins in HBF were com-
parable to those detected in peripheral blood leukocytes
(Figure 1B), the generation of their lipid products after
ionophore stimulation was modest in comparison
[22,23]. This finding suggests that a factor other than the
amounts of 5-LO and its downstream enzymes may deter-
mine the maximal amounts of LT produced, including the
activity of the proximal phospholipases A2 that mobilize
arachidonate from membrane phospholipids. Further
experiments in the presence of exogenous arachidonate
may elucidate this question.
The data nevertheless add cysteinyl-LTs and LTB4 to the
growing list of autacoids, cytokines and growth factors
known to be generated by primary HBF, including pros-
taglandin E2, IL-1, IL-6, IL-13, granulocyte-colony stimu-
lating factor, granulocyte macrophage-colony stimulating
factor and eotaxin [1,24]. As the predominant stromal
cell-type in the bronchial submucosa, even low levels of
production of cysteinyl-LTs by HBF in asthma may con-
tribute substantially to bronchial smooth muscle contrac-
tion, microvascular permeability, mucus hypersecretion
and eosinophil recruitment [5]. The latter may arise
through direct effects at CysLT1 receptors on the eosi-
nophil surface, or indirectly via the secondary release of
Table 3: Effects of cytokines, autacoids and leukotrienes on 5-LO pathway enzymes and LT receptors in HBFs.
Control* EGF Cytomix LTB4 LTD4 BK HIS
5-LO 9.1 ± 2.0 8.8 ± 2.4 9.4 ± 3.6 10.5 ± 3.2 9.5 ± 2.4 10.8 ± 2.9 6.4 ± 1.9†
FLAP 11.4 ± 2.8 11.3 ± 4.2 12.2 ± 3.7 10.5 ± 2.2 11.8 ± 3.2 11.2 ± 2.7 11.3 ± 3.6
LTA4H 8.2 ± 2.0 9.3 ± 2.3 10.1 ± 2.4 9.2 ± 2.2 9.1 ± 1.9 5.8 ± 1.1 9.8 ± 2.5
LTC4S 1.5 ± 0.7 1.2 ± 0.3 0.8 ± 0.5 0.8 ± 0.3‡ 1.0 ± 0.5 1.0 ± 0.3 1.1 ± 0.4
BLT1 8.8 ± 2.3 14.2 ± 5.0 13.5 ± 4.9 12.8 ± 4.6 10.9 ± 4.5 11.5 ± 4.2 11.2 ± 4.7
CysLT1 6.7 ± 1.4 7.5 ± 2.1 14.3 ± 4.5 12.0 ± 5.7 7.8 ± 1.5 8.5 ± 1.4 9.9 ± 1.7
* Fibroblasts were cultured for 24 hours with either EGF (10 ng/ml), a combination of IL-1β, TNF-α and IFN-γ (Cytomix, each at 10 ng/ml), LTB4 
(10 nM), LTD4 (10 nM), bradykinin (BK, 10 μM), histamine (HIS, 10 μM) or control medium before staining with specific antibodies and analysis by 
flow cytometry.
† p = 0.047 versus Control
‡ p = 0.036 versus Control
Table 2: Immunofluorescence for 5-LO pathway enzymes and LT 
receptors in fibroblasts from normal and asthmatic donors.
Enzyme/Receptor Normal*(Mean 
MFI ± SEM n = 5)
Asthmatic (Mean 
MFI ± SEM n = 5)
5-LO 9.7 ± 2.8 8.5 ± 3.1
FLAP 12.3 ± 3.8 10.5 ± 4.5
LTA4H 7.8 ± 1.9 8.6 ± 3.7
LTC4S 0.97 ± 0.4 2.1 ± 1.4
BLT1 10.5 ± 3.1 6.7 ± 3.6
CysLT1 7.9 ± 1.4 5.5 ± 2.4
* Fibroblasts from 5 normal subjects and 5 asthmatic patients were 
stained with specific antibodies to 5-LO, FLAP, LTA4H, LTC4S, BLT1 
and CysLT1R before analysis by flow cytometry.Respiratory Research 2006, 7:102 http://respiratory-research.com/content/7/1/102
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eotaxin from fibroblasts triggered by autocrine or para-
crine cysteinyl-LTs [24]. Similarly, the generation of LTB4
by HBF may contribute to infiltration of the airway by
neutrophils and monocytes in response to inhaled irri-
tants [25,26].
Our study showed for the first time that primary fibrob-
lasts from normal and asthmatic bronchi constitutively
express both mRNA and protein for CysLT1  receptors
under baseline conditions (Figures 1,2,3, Table 2).
Human nasal polyp fibroblasts and the human fetal lung
fibroblast cell line HFL-1 are not thought to constitutively
express CysLT1  receptor protein[24,27], although its
expression on HFL-1 cells is inducible by IL-13 [24].
CysLT1 receptor expression may be absent in fetal lung
fibroblasts in vivo or it may be lost during the 27 passages
endured by the HFL-1 cell line. The HBF in our study were
examined between passages five and seven. The CysLT1
receptors observed on adult HBF may mediate the effects
of autocrine or exogenous cysteinyl-LTs on fibroblast pro-
liferation and collagen deposition [8,9], and also mediate
fibroblast apoptosis induced by oxidant injury [28]. As
well as CysLT1 receptors, HBF also constitutively expressed
the BLT1 receptor, which is normally thought to be
restricted to myeloid leukocytes in which it mediates
chemotaxis to LTB4 [13]. This may underlie the ability of
nanomolar concentrations of LTB4 to induce chemotaxis
in human fibroblasts in vitro [29,30].
Having established the baseline expression of 5-LO path-
way enzymes and LT receptors in HBFs, we then investi-
gated whether their expression is modulated when
fibroblasts are transformed to myofibroblasts, a pheno-
type intermediate between fibroblasts and myocytes char-
acterized by contractility and extracellular matrix
deposition. The most potent inducer of myofibroblast dif-
ferentiation is TGF-β [17,31]. Compared to cultures in
DMEM/10%FCS, which itself contains some serum-
derived TGF-β, treatment for three days with exogenous
TGF-β1 (10 ng/ml) up-regulated expression of the contrac-
tile proteins, α-smooth muscle actin and myosin heavy
chain, it was shown that this is associated with marked
increases in LTC4 synthase and CysLT1 receptors, and with
a decline in expression of LTA4 hydrolase and BLT1 recep-
tors (Figure 4). This suggests that the myofibroblast phe-
notype may be linked with an enhanced capacity to
synthesize and respond to cysteinyl-LTs, and with a corre-
sponding decline in ability to synthesize and respond to
LTB4. That this was not associated with changes at the
level of synthesized lipid product under the conditions
used suggests an additional level of regulation, perhaps at
the level of the proximal phospholipases, that requires
further investigation. As the activities of LTB4 and cystei-
nyl-LTs may be regarded as chemotactic and pro-fibrotic
Table 4: Effects of dexamethasone and MK-571 on 5-LO pathway 
enzymes and LT receptors in HBFs.
Enzymes/Receptors Control* Dexamethasone MK-571
5-LO 7.6 ± 2.2 5.7 ± 2.0† 7.5 ± 2.6
FLAP 9.3 ± 3.3 6.3 ± 2.5 5.3 ± 2.0‡
LTA4H 7.8 ± 2.1 5.3 ± 1.6† 5.2 ± 0.9
LTC4S 0.3 ± 0.2 0.7 ± 0.4 0.5 ± 0.2‡
BLT1 4.8 ± 1.1 4.5 ± 1.3 3.9 ± 0.9
CysLT1 11.7 ± 3.5 5.6 ± 1.4 16.0 ± 6.9
* Fibroblasts were cultured for 24 hours with the glucocorticoid 
dexamethasone (1 μM), the CysLT1 receptor antagonist MK-571 (10 
nM), or control medium before staining with specific antibodies then 
analyzed by flow cytometry (Mean ± SEM, n = 9).
† Non-significant trend towards reduced expression compared to 
control, p = 0.066.
‡ p ≤ 0.05 versus Control.
Synthesis of cysteinyl-LTs and LTB4 by human bronchial  fibroblasts Figure 5
Synthesis of cysteinyl-LTs and LTB4 by human bron-
chial fibroblasts. Fibroblasts were cultured for 72 hours in 
the presence or absence of TGF-β1 (10 ng/ml) before they 
were washed and stimulated for a further 2 hours with cal-
cium ionophore A23187 (1 μM, filled column) or vehicle 
(open column). Levels of total cysteinyl-LTs (LTC4D4E4) (A) 
and LTB4 (B) in culture supernatants were then measured by 
EIA. Mean ± SEM (n = 9).
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respectively, these changes are nevertheless consistent
with the association of the fibroblast with inflammatory
leukocyte recruitment and activation and the myofibrob-
last with contractility.
We next investigated the in vitro effects of a range of factors
associated with asthma and fibrosis that might modulate
the LT pathway in fibroblasts (Table 3). At the concentra-
tions used and in 24-hour incubations, there were no
meaningful effects of leukotrienes B4 and D4, the CysLT1
antagonist MK-571, histamine, bradykinin, EGF, or pro-
inflammatory cytokines (IL-1β, TNF-α and IFN-γ) on the
expression of 5-LO pathway proteins and LT receptors. In
the light of the ability of IL-13 to up-regulate CysLT1 in
HFL-1 cells [24], and the contrasting failure of IL-4 to
induce CysLT1  or the 5-LO/LTC4  synthase pathway in
nasal polyp fibroblasts [27], it would be of interest to
investigate the effects of these Th2-type cytokines on 5-LO
pathway enzymes and LT receptors in primary lung
fibroblasts. The impact of glucocorticoids on the 5-LO
pathway is variable, with paradoxical upregulation of 5-
LO and FLAP being seen in leukocytes [18,32]. The lack of
effect of dexamethasone on 5-LO pathway enzymes in
HBF (Table 4) is consistent with their lack of effect on leu-
kocyte production of leukotrienes and the failure of gluco-
corticoid therapy to alter LT levels in vivo [33].
Lung fibroblasts from asthmatic subjects have been
reported to display persistent phenotypic anomalies com-
pared to normal fibroblasts, including exaggerated prolif-
erative responses even in the absence of mitogens [34].
We hypothesized that asthmatic fibroblasts might also
have an upregulated 5-LO pathway or enhanced LT recep-
tor expression. An enhanced capacity for LT synthesis has
been observed in the mast cells and PBL of asthmatics
compared with normal cells, associated with increased
expression of FLAP and other 5-LO pathway
enzymes[18,23,35]. However, in HBF, there were no dif-
ferences between the normal and asthmatic donors in
basal immunofluorescence for 5-LO pathway enzymes or
LT receptors (Table 2), or in their capacity to synthesize
LTB4 and cysteinyl-LTs, nor did any differences emerge
when cells from the two groups were treated with TGF-β1
or with calcium ionophore A23187. This may reflect the
relatively small numbers of subjects in our study (n = 5 in
each group), or such differences might exist in vivo but be
lost during cell culture even within 5–7 passages.
Conclusion
Our study has revealed that in contrast to human fetal
lung fibroblast cell lines [24], primary fibroblasts from the
bronchi of normal and asthmatic adults constitutively
express CysLT1 receptors, and that this receptor is up-reg-
ulated by transformation of fibroblasts to a contractile
myofibroblast phenotype, while the constitutive expres-
sion of BLT1 receptors may explain fibroblast chemotactic
responses to LTB4. The study has identified for the first
time in human bronchial fibroblasts the presence of a
complete 5-LO enzymatic pathway that actively synthe-
sizes cysteinyl-LTs and LTB4 at baseline, and in increased
amounts after calcium-dependent activation. In the air-
ways, in disorders such as asthma, these LTs might pro-
mote migration and collagen deposition by fibroblasts in
an autocrine manner leading to sub-epithelial fibrosis, as
well as promoting other remodeling responses in adjacent
tissues including the proliferation of epithelial cells and
airway smooth muscle [7].
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